Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Olaparib & Breast Cancer / Mammacarcinoma (BRCA m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Olaparib is FDA approved for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic Breast Cancer / Mammacarcinoma (BRCA m)
Tung et al. 2020a JCO 38: 4274-4282

Olaparib demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast cancer.
Griguolo et al. 2018 Expert Review of Anticancer Therapy 18: 519-530

Olaparib improves progression-free survival (PFS) in germline BRCA mutated HER2 negative metastatic breast cancer patients as compared to standard chemotherapy, with a manageable toxicity profile.
Griguolo et al. 2018 Expert Review of Anticancer Therapy 18: 519-530

…

References (Sources)

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Tutt et al. 2021a N Engl J Med 384: 2394-2405
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Heymach et al. 2018
Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
Hilal et al. 2020 JAMA Intern. Med. 180: 1108
Olaparib for advanced breast cancer
Griguolo et al. 2020 Future Oncology 16: 717-732
Olaparib for the treatment of breast cancer
Griguolo et al. 2018 Expert Review of Anticancer Therapy 18: 519-530
Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial
Armstrong & Clay 2019 Future Oncology 15: 2327–2335
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Tung et al. 2020a JCO 38: 4274-4282

AI Chat

7/1/2026

Chat with our artificial intelligence: